Indications that the Federal Reserve will not raise interest rates sent the markets soaring to a sharply higher open with the Dow jumping 185 points to 16,658. Nasdaq surged 49 points to 4,756.
On the upside
ContraVir Pharmaceuticals (Nasdaq: CTRV) reported preliminary positive data for its CMX157 to treat hepatitis B.
Bargain hunters continued to snap up shares of Amicus Therapeutics (Nasdaq: FOLD).
Spark Therapeutics (Nasdaq: ONCE) reported upbeat data from a Phase 3 trial of SPK-RPE65.
On the downside
Citron tweeted that Valeant Pharmaceuticals (NYSE: VRX) was a lemon.
Piper Jaffray downgraded FireEye (Nasdaq: FEYE) from an Overweight rating to a Neutral rating.
The Brazilian regulatory agency ANVISA temporarily suspended activity at a contract manufacturer for Sientra (Nasdaq: SIEN).
In the broad market, advancing issues outpaced decliners by a margin of nearly 8 to 1 on the NYSE and by more than 5 to 1 on Nasdaq. The broader S&P 500 leaped 24 points to 1,975. Bitcoin edged up a fraction to $237.
Rate hike delay sends markets soaring
October 05, 2015 at 10:43 AM EDT
